Trump Medicare drug pricing model may apply to only four companies after exemptions

A finalized Trump administration rule aimed at reducing Medicare hospital drug prices could apply to as few as four drugmakers after exemptions were granted to companies that entered separate “most favored nation” pricing agreements. The limited scope may reduce the policy’s broader financial impact on the pharmaceutical sector while preserving targeted pricing pressure on the remaining companies.